PL205957B1 - Podstawione pirydyny i pirydazyny z aktywnością hamowania angiogenezy, kompozycje farmaceutyczne je zawierające i ich zastosowanie do wytwarzania leków - Google Patents

Podstawione pirydyny i pirydazyny z aktywnością hamowania angiogenezy, kompozycje farmaceutyczne je zawierające i ich zastosowanie do wytwarzania leków

Info

Publication number
PL205957B1
PL205957B1 PL366342A PL36634200A PL205957B1 PL 205957 B1 PL205957 B1 PL 205957B1 PL 366342 A PL366342 A PL 366342A PL 36634200 A PL36634200 A PL 36634200A PL 205957 B1 PL205957 B1 PL 205957B1
Authority
PL
Poland
Prior art keywords
methyl
pyridazin
oxy
amino
furo
Prior art date
Application number
PL366342A
Other languages
English (en)
Polish (pl)
Other versions
PL366342A1 (en
Inventor
Jacques P. Dumas
Teddy Kite Joe
Harold C.E. Kluender
Wendy Lee
Dhanapalan Nagarathnam
Robert N. Sibley
Ning Su
Stephen James Boyer
Julie A. Dixon
Original Assignee
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Corp filed Critical Bayer Corp
Publication of PL366342A1 publication Critical patent/PL366342A1/xx
Publication of PL205957B1 publication Critical patent/PL205957B1/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
PL366342A 1999-09-28 2000-09-26 Podstawione pirydyny i pirydazyny z aktywnością hamowania angiogenezy, kompozycje farmaceutyczne je zawierające i ich zastosowanie do wytwarzania leków PL205957B1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40760099A 1999-09-28 1999-09-28

Publications (2)

Publication Number Publication Date
PL366342A1 PL366342A1 (en) 2005-01-24
PL205957B1 true PL205957B1 (pl) 2010-06-30

Family

ID=23612752

Family Applications (1)

Application Number Title Priority Date Filing Date
PL366342A PL205957B1 (pl) 1999-09-28 2000-09-26 Podstawione pirydyny i pirydazyny z aktywnością hamowania angiogenezy, kompozycje farmaceutyczne je zawierające i ich zastosowanie do wytwarzania leków

Country Status (35)

Country Link
EP (1) EP1228063B1 (show.php)
JP (1) JP4919567B2 (show.php)
KR (3) KR100890473B1 (show.php)
CN (3) CN100374435C (show.php)
AR (3) AR025752A1 (show.php)
AT (1) ATE422494T1 (show.php)
AU (1) AU782820B2 (show.php)
BG (1) BG65860B1 (show.php)
BR (1) BRPI0014382B8 (show.php)
CA (1) CA2385817C (show.php)
CO (1) CO5200835A1 (show.php)
CZ (1) CZ304767B6 (show.php)
DE (1) DE60041548D1 (show.php)
DO (1) DOP2000000070A (show.php)
EE (1) EE05258B1 (show.php)
ES (1) ES2320525T3 (show.php)
GT (1) GT200000158A (show.php)
HR (1) HRP20020308A2 (show.php)
HU (1) HU230223B1 (show.php)
IL (3) IL148880A0 (show.php)
MA (1) MA25563A1 (show.php)
MX (1) MXPA02003156A (show.php)
MY (3) MY143580A (show.php)
NO (1) NO20021520L (show.php)
NZ (1) NZ518589A (show.php)
PA (1) PA8503201A1 (show.php)
PE (1) PE20010607A1 (show.php)
PL (1) PL205957B1 (show.php)
RS (1) RS50369B (show.php)
RU (1) RU2260008C2 (show.php)
SK (1) SK287417B6 (show.php)
TW (1) TW593315B (show.php)
UA (1) UA75053C2 (show.php)
WO (1) WO2001023375A2 (show.php)
ZA (1) ZA200202760B (show.php)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0113078A (pt) * 2000-08-09 2003-07-01 Astrazeneca Ab Uso de um composto, composto, processo para a preparação do mesmo, composição farmacêutica, e, método para produzir um efeito antiangiogênico e/ou redutor da permeabilidade vascular em um animal de sangue quente
HU230302B1 (hu) 2000-10-20 2015-12-28 Eisai R&D Management Co., Ltd. Nitrogéntartalmú aromás származékok és ezeket tartalmazó gyógyászati készítmények
JP2006503796A (ja) * 2001-12-21 2006-02-02 バイエル・フアーマシユーチカルズ・コーポレーシヨン ピリダジンまたはピリジン誘導体を含んでなる抗−脈管形成組み合わせ療法
TWI299664B (en) 2003-01-06 2008-08-11 Osi Pharm Inc (2-carboxamido)(3-amino)thiophene compounds
ES2318276T3 (es) * 2003-03-11 2009-05-01 Novartis Ag Uso de los derivados de la isoquinolina para tratar el cancer y las enfermedades relacionadas con la quinasa map.
EP1616576A4 (en) * 2003-04-08 2010-02-10 Mitsubishi Tanabe Pharma Corp SPECIFIC NAD (P) H OXIDASE HEMMER
CN100450998C (zh) 2003-11-11 2009-01-14 卫材R&D管理有限公司 脲衍生物的制备方法
KR100553398B1 (ko) * 2004-03-12 2006-02-16 한미약품 주식회사 티에노[3,2-c]피리딘 유도체의 제조 방법 및 이에사용되는 중간체
US8772269B2 (en) 2004-09-13 2014-07-08 Eisai R&D Management Co., Ltd. Use of sulfonamide-including compounds in combination with angiogenesis inhibitors
WO2006030941A1 (ja) 2004-09-13 2006-03-23 Eisai R & D Management Co., Ltd. スルホンアミド含有化合物の血管新生阻害物質との併用
EP1797881B1 (en) 2004-09-17 2009-04-15 Eisai R&D Management Co., Ltd. Medicinal composition with improved stability and reduced gelation properties
EP2281901B1 (en) 2005-08-02 2013-11-27 Eisai R&D Management Co., Ltd. Anti-tumour pharmaceutical composition with angiogenesis inhibitors
US8304406B2 (en) 2006-04-15 2012-11-06 Bayer Intellectual Property Gmbh Compounds for treating pulmonary hypertension
EP2036557B1 (en) 2006-05-18 2015-10-21 Eisai R&D Management Co., Ltd. Antitumor agent for thyroid cancer
CN101511793B (zh) 2006-08-28 2011-08-03 卫材R&D管理有限公司 针对未分化型胃癌的抗肿瘤剂
AU2008211952B2 (en) 2007-01-29 2012-07-19 Eisai R & D Management Co., Ltd. Composition for treatment of undifferentiated-type of gastric cancer
JP5638244B2 (ja) 2007-11-09 2014-12-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質と抗腫瘍性白金錯体との併用
CN101481380B (zh) * 2008-01-08 2012-10-17 浙江医药股份有限公司新昌制药厂 噻吩并哒嗪类化合物及其制备方法、药物组合物及其用途
MX2012014776A (es) 2010-06-25 2013-01-29 Eisai R&D Man Co Ltd Agente antitumoral que emplea compuestos con efecto inhibidor de cinasas combinados.
MX2013009931A (es) 2011-04-18 2013-10-01 Eisai R&D Man Co Ltd Agentes terapeuticos contra tumores.
US9945862B2 (en) 2011-06-03 2018-04-17 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
US9334239B2 (en) 2012-12-21 2016-05-10 Eisai R&D Management Co., Ltd. Amorphous form of quinoline derivative, and method for producing same
US10517861B2 (en) 2013-05-14 2019-12-31 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
CN103396361B (zh) * 2013-07-24 2016-05-04 中国人民解放军第二军医大学 3,4-二氢异喹啉类抗肿瘤化合物及其制备方法与应用
CN106660964B (zh) 2014-08-28 2021-09-03 卫材R&D管理有限公司 高纯度喹啉衍生物及其生产方法
PL3263106T3 (pl) 2015-02-25 2024-04-02 Eisai R&D Management Co., Ltd. Sposób tłumienia goryczy pochodnej chinoliny
KR102662228B1 (ko) 2015-03-04 2024-05-02 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
CN104804008B (zh) * 2015-03-27 2016-03-23 亿腾药业(泰州)有限公司 一种工业化生产甲磺酸特拉替尼的方法
ES2886107T3 (es) 2015-06-16 2021-12-16 Prism Biolab Co Ltd Antineoplásico
AU2016309356B2 (en) 2015-08-20 2021-06-24 Eisai R&D Management Co., Ltd. Tumor therapeutic agent
MX380144B (es) 2017-02-08 2025-03-12 Eisai R&D Man Co Ltd Composicion farmaceutica de tratamiento de tumores.
CN107129502B (zh) * 2017-04-13 2022-08-05 泰州亿腾景昂药业股份有限公司 EOC315 Mod.I晶型化合物及其制备方法
CA3061888A1 (en) 2017-05-16 2018-11-22 Eisai R&D Management Co., Ltd. Treatment of hepatocellular carcinoma
EP3959214A1 (en) * 2019-04-22 2022-03-02 Mirati Therapeutics, Inc. Naphthyridine derivatives as prc2 inhibitors
CN112830932B (zh) * 2020-12-25 2022-04-08 泰州亿腾景昂药业股份有限公司 特拉替尼的游离碱晶型及其制备方法与用途
JP2024540411A (ja) 2021-11-08 2024-10-31 プロジェントス・セラピューティクス・インコーポレイテッド 血小板由来成長因子受容体(pdgfr)アルファ阻害剤及びその使用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1453897A (fr) * 1965-06-16 1966-07-22 Dérivés du thiophène et de thiéno pyridazines
GB1094044A (en) * 1965-07-12 1967-12-06 Vantorex Ltd Phthalazine derivatives
FR1516777A (fr) * 1966-08-02 1968-02-05 Innothera Lab Sa Dérivés du thiazole ainsi que de la thiazolo [4,5-d] pyridazine et leur préparation
GB1293565A (en) * 1969-05-03 1972-10-18 Aspro Nicholas Ltd Aminophthalazines and pharmaceutical compositions thereof
JPH03106875A (ja) * 1989-09-20 1991-05-07 Morishita Pharmaceut Co Ltd 1―(3―ピリジルメチル)フタラジン誘導体
WO1996005176A1 (en) * 1994-08-09 1996-02-22 Eisai Co., Ltd. Fused pyridazine compound
IL118631A (en) * 1995-06-27 2002-05-23 Tanabe Seiyaku Co History of pyridazinone and processes for their preparation
CO4950519A1 (es) * 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
ATE459616T1 (de) * 1998-08-11 2010-03-15 Novartis Ag Isochinoline derivate mit angiogenesis-hemmender wirkung
CA2366857C (en) * 1999-03-30 2010-12-14 Novartis Ag Phthalazine derivatives for treating inflammatory diseases
AR025068A1 (es) * 1999-08-10 2002-11-06 Bayer Corp Pirazinas sustituidas y piridazinas fusionadas, composicion farmaceutica que las comprenden, uso de dichos compuestos para la manufactura de un medicamentocon actividad inhibidora de angiogenesis
AU2001231710A1 (en) * 2000-02-09 2001-08-20 Novartis Ag Pyridine derivatives inhibiting angiogenesis and/or vegf receptor tyrosine kinase

Also Published As

Publication number Publication date
CA2385817A1 (en) 2001-04-05
MY143377A (en) 2011-05-13
SK5912002A3 (en) 2003-01-09
CN1769282A (zh) 2006-05-10
MY143580A (en) 2011-05-31
EE200200161A (et) 2003-08-15
EP1228063B1 (en) 2009-02-11
BG65860B1 (bg) 2010-03-31
AU1569601A (en) 2001-04-30
HUP0202704A3 (en) 2003-12-29
ZA200202760B (en) 2003-10-29
CN1769283A (zh) 2006-05-10
CO5200835A1 (es) 2002-09-27
ATE422494T1 (de) 2009-02-15
TW593315B (en) 2004-06-21
BR0014382B1 (pt) 2014-04-01
KR20080091505A (ko) 2008-10-13
AR082231A2 (es) 2012-11-21
NZ518589A (en) 2005-03-24
NO20021520D0 (no) 2002-03-26
KR100890473B1 (ko) 2009-03-26
KR100895571B1 (ko) 2009-04-29
CN100422173C (zh) 2008-10-01
IL148880A0 (en) 2002-09-12
MXPA02003156A (es) 2002-09-30
HK1091819A1 (zh) 2007-01-26
AU782820B2 (en) 2005-09-01
AR082232A2 (es) 2012-11-21
NO20021520L (no) 2002-05-23
UA75053C2 (en) 2006-03-15
MY135058A (en) 2008-01-31
IL193367A (en) 2011-03-31
KR100895572B1 (ko) 2009-04-29
AR025752A1 (es) 2002-12-11
RS50369B (sr) 2009-11-10
CN100422172C (zh) 2008-10-01
DE60041548D1 (de) 2009-03-26
KR20020038775A (ko) 2002-05-23
PL366342A1 (en) 2005-01-24
PA8503201A1 (es) 2002-08-26
CN100374435C (zh) 2008-03-12
WO2001023375A3 (en) 2002-05-02
DOP2000000070A (es) 2002-02-28
IL193368A (en) 2011-05-31
CZ304767B6 (cs) 2014-10-08
HUP0202704A2 (hu) 2002-12-28
JP2003526632A (ja) 2003-09-09
CN1420879A (zh) 2003-05-28
BR0014382A (pt) 2003-06-24
WO2001023375A2 (en) 2001-04-05
CA2385817C (en) 2010-05-04
ES2320525T3 (es) 2009-05-25
GT200000158A (es) 2002-03-16
RU2260008C2 (ru) 2005-09-10
IL193367A0 (en) 2009-02-11
SK287417B6 (sk) 2010-09-07
HRP20020308A2 (en) 2004-06-30
YU22902A (sh) 2004-12-31
PE20010607A1 (es) 2001-07-12
MA25563A1 (fr) 2002-10-01
EE05258B1 (et) 2010-02-15
HU230223B1 (en) 2015-10-28
BRPI0014382B8 (pt) 2021-05-25
CZ20021444A3 (cs) 2002-08-14
IL193368A0 (en) 2009-02-11
HRP20020308B1 (show.php) 2013-01-31
EP1228063A2 (en) 2002-08-07
JP4919567B2 (ja) 2012-04-18
HK1091818A1 (zh) 2007-01-26
KR20080086547A (ko) 2008-09-25
BG106637A (bg) 2003-02-28

Similar Documents

Publication Publication Date Title
PL205957B1 (pl) Podstawione pirydyny i pirydazyny z aktywnością hamowania angiogenezy, kompozycje farmaceutyczne je zawierające i ich zastosowanie do wytwarzania leków
EP1208096B1 (en) Substituted pyridazines and fused pyridazines with angiogenesis inhibiting activity
US6689883B1 (en) Substituted pyridines and pyridazines with angiogenesis inhibiting activity
US6903101B1 (en) Substituted pyridazines and fused pyridazines with angiogenesis inhibiting activity
US20110263597A1 (en) Substituted pyridines and pyridazines with angiogenesis inhibiting activity
HK1091819B (en) Substitued pyridines and pyridazines with angiogenesis inhibiting activity
HK1091818B (en) Substitued pyridines and pyridazines with angiogenesis inhibiting activity